Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Trial Profile

The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Binge-eating disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 26 Feb 2019 Results of the post-hoc analysis assessing characteristics and lisdexamfetamine dimesylate treatment effects, based on gender and age, in adults diagnosed with moderate to severe binge eating disorder pooling data from NCT01718483 and NCT01718509, published in the Journal of Clinical Psychiatry
    • 09 May 2018 Results (n=724) of post hoc analysis of 2 identically designed phase 3 studies (NCT01718509 and NCT01718483) presented at the 171st Annual Meeting of the American Psychiatric Association
    • 11 Nov 2015 Pooled, post-hoc analysis results of two placebo controlled trials, presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top